The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Open accessPublished version of a preprint
Abstract
Purpose: CTLA-4 was the first inhibitory immune checkpoint to be identified. Two mAbs, ipilimumab (IgG1) and tremelimumab (IgG2), which block the function of CTLA-4, have demonstrated durable clinical activity in a subset of patients with advanced solid malignancies by augmenting effector T-cell–mediated immune responses. Studies in mice suggest that anti-CTLA-4 mAbs may also selectively deplete intratumoral FOXP3+ regulatory T cells via an Fc-dependent mechanism. However, it is unclear whether the depletion of FOXP3+ cells occurs in patients with cancer treated with anti-CTLA-4 therapies. Experimental Design: Quantitative IHC was used to evaluate the densities of intratumoral CD4+, CD8+, and FOXP3+ cells in stage-matched melanoma (n = 19), prostate cancer (n = 17), and bladder cancer (n = 9) samples treated with ipilimumab and in paired melanoma tumors (n = 18) treated with tremelimumab. These findings were corroborated with multiparametric mass cytometry analysis of tumor-infiltrating cells from paired fresh melanoma tumors (n = 5) treated with ipilimumab. Results: Both ipilimumab and tremelimumab increase infiltration of intratumoral CD4+ and CD8+ cells without significantly changing or depleting FOXP3+ cells within the tumor microenvironment. Conclusions: Anti-CTLA-4 immunotherapy does not deplete FOXP3+ cells in human tumors, which suggests that their efficacy could be enhanced by modifying the Fc portions of the mAbs to enhance Fc-mediated depletion of intratumoral regulatory T cells. See related commentary by Quezada and Peggs, p. 1130
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Anti-CTLA-4 therapy has been somewhat effective in melanoma and several other cancers, and blockade of the PD-1/PD-L1 axis is now first-line therapy for various tumor types, particularly melanoma and non-small cell lung carcinoma, with their combination being superior at the expense of enhanced adverse effects359,360.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [359]
In the citing paper
“Anti-CTLA-4 therapy has been somewhat effective in melanoma and several other cancers, and blockade of the PD-1/PD-L1 axis is now first-line therapy for various tumor types, particularly melanoma and non-small cell lung carcinoma, with their combination being superior at the expense of enhanced adverse effects359,360.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [359]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“CTL-associated protein 4 (CTLA-4) is an inhibitory immune checkpoint receptor that plays a crucial role in modulating T-cell responses (1, 2).”
BackgroundSelf-citationTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,996
Amir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Self-citationFOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT
Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A. D., Stroud, J. C., Bates, D. L., Guo, L., Han, A., Ziegler, S. F., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.042 · Cited by 1,229
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Self-citationCombination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×
“Clinical studies have been unclear in defining the role of IgG1 ipilimumab and IgG2 tremelimumab in depleting intratumoral Tregs in human cancers (9, 22).”
BackgroundSelf-citationSelby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
Foxp3 in control of the regulatory T cell lineage
Zheng, Y., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1455 · Cited by 707
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“preclinical and clinical studies (3, 6, 18, 19, 28), and it has emerged as a paradigm shift in cancer therapy.”
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650
Self-citationRomano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549 · cited 3×
“We observed an increase in the number of total T cells, but a decrease in frequency of FOXP3 + Tregs, which was measured as a percent of total cells (24, 25).”
Self-citationCarthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460
Self-citationBlockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Self-citationJain, N., Nguyen, H., Chambers, C. A., & Kang, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910341107 · Cited by 253
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Du, X., Tang, F., Liu, M., Su, J., Zhang, Y., Wu, W., Devenport, M., Lazarski, C. A., Zhang, P., Wang, X., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0011-0 · Cited by 253
CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
Yeap, W. H., Wong, K. L., Shimasaki, N., Teo, E. C. Y., Quek, J. K. S., Yong, H. X., Diong, C. P., Bertoletti, A., Linn, Y. C., & Wong, S. C. (2016) · Scientific Reports · doi:10.1038/srep34310 · Cited by 230
Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157
Self-citationClinical Development of the Anti–CTLA-4 Antibody Tremelimumab
Ribas, A. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.010 · Cited by 134
Self-citationRibas, A., Comı́n-Anduix, B., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris, L. F., Jalil, J., Dissette, V. B., Shintaku, I. P., Glaspy, J. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0783 · Cited by 132
Self-citationInfluence of immunoglobulin isotype on therapeutic antibody function
Beers, S. A., Glennie, M. J., & White, A. L. (2016) · Blood · doi:10.1182/blood-2015-09-625343 · Cited by 124
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Wada, S., Jackson, C. M., Yoshimura, K., Yen, H., Getnet, D., Harris, T. J., Goldberg, M. V., Bruno, T. C., Grosso, J. F., Durham, N. M., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-89 · Cited by 95
Retseck, J., VanderWeele, R. A., Lin, H., Lin, Y., Butterfield, L. H., & Tarhini, A. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0141-1 · Cited by 25
Cited by
Sorted by citations
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 972
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Self-citation
Metadata
- Authors
- Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2019-02-15
- Volume
- 25
- Issue
- 4
- Pages
- 1233-1238
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC6348141
- OpenAlex
- W4253193856
- Cited by
- 382
- References
- 33
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 62 · 2023: 40 · 2022: 60 · 2021: 60 · 2020: 49 · 2019: 43
- FWCI
- 15.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- HHS | NIH | National Cancer Institute (NCI) (R01 CA1633793)
- Prostate Cancer Foundation (PCF) (2014 Stewart Rahr-PCF Young Investigator)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, anti-CTLA-4 immunotherapy, Foxp3+ regulatory T cells, ipilimumab, tremelimumab, tumor-infiltrating lymphocytes, tumor microenvironment, melanoma, prostate cancer, bladder cancer, mass cytometry, immune checkpoint blockade
- MeSH terms
- Ipilimumab, Urinary Bladder Neoplasms, Female, Humans, Male, Melanoma, Prostatic Neoplasms, CD4-Positive T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Paraffin Embedding, CD8-Positive T-Lymphocytes, Cell Lineage, Forkhead Transcription Factors, Tumor Microenvironment, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
